Compare MCY & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCY | RYTM |
|---|---|---|
| Founded | 1961 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 1995 | 2017 |
| Metric | MCY | RYTM |
|---|---|---|
| Price | $104.15 | $94.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $140.53 |
| AVG Volume (30 Days) | 220.8K | ★ 613.6K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | 15.62 | ★ 28.34 |
| EPS | ★ 8.20 | N/A |
| Revenue | ★ $5,992,468,000.00 | N/A |
| Revenue This Year | $4.51 | $66.14 |
| Revenue Next Year | $6.66 | $79.25 |
| P/E Ratio | $12.50 | ★ N/A |
| Revenue Growth | ★ 9.44 | N/A |
| 52 Week Low | $76.00 | $74.50 |
| 52 Week High | $113.06 | $122.20 |
| Indicator | MCY | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 55.32 |
| Support Level | $100.24 | $82.92 |
| Resistance Level | $107.88 | $94.94 |
| Average True Range (ATR) | 2.33 | 2.93 |
| MACD | -0.03 | 1.12 |
| Stochastic Oscillator | 56.72 | 90.26 |
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The company offers the following types of automobile coverage: collision, property damage, bodily injury (BI), comprehensive, personal injury protection (PIP), underinsured and uninsured motorist, and other hazards. Additionally, it offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages. The company has one reportable business segment, the Property and Casualty business segment.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.